Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oreterra Reports Bornite, Chalcopyrite and Magnetite Mineralization with Strong Porphyry Style Alteration in Trek South Drill Hole TS26-06; Drilling Continuing
QIMC Drills New Company Record of 27.8% Clean Natural Hydrogen at Just 374 Metres at Bennett Hill, Nova Scotia
Nine Mile Metals DDH WD-26-07 Intersects High Grade VMS Zones Including 24m of 2.77% Cu-Eq and 9.2m of 4.14% Cu-Eq
NevGold Expands Recent Mineral Resource Estimate With First 2026 Drillholes; 1.16% Antimony Over 3.0 Meters Within 1.38 g/t AuEq Over 50.3 Meters From Surface
